Home › RetroSense Therapeutics Granted Orphan Drug Designation For Lead Product RST-001 For Retinitis Pigmentosa
 

Keywords :   


RetroSense Therapeutics Granted Orphan Drug Designation For Lead Product RST-001 For Retinitis Pigmentosa

2014-11-05 05:53:53| drugdiscoveryonline Home Page

RetroSense Therapeutics, LLC, a privately-held biopharmaceutical company, announced recently that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for the Company’s lead product RST-001 for the treatment of retinitis pigmentosa (RP)

Tags: product lead drug granted

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
05.11Shoppers warned over luxury advent calendar scams
05.11Durable Floor Coating from HMG Paints Transforms FC United\'s SMRE Bar
05.11Teknos Poland Honored by Farby i Lakiery
05.11Xumo teams up with Target to offer Hisense Xumo TVs
05.11KT launches 8K AI-powered IPTV set-top box
05.11Tropical Storm Rafael Graphics
More »